Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

← catalyst calendar

NCT05989711

Sponsored by Altimmune, Inc. (industry) · ALT — their whole pipeline →.

Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
212actual
Sites
40
Countries
Australia, Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-07-27actualWhen the study began enrolling
Primary completion2025-11-25actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-11-25actualThe whole study's end, after follow-up
First posted2023-08-14actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-05-18actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

  • Drug: Pemvidutide
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis
measured 24 weeks
Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)
measured 24 weeks
Incidence of Treatment Emergent Adverse Events
measured 52 weeks

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ALT's whole pipeline · Catalyst calendar · Every registered study · What changed